The Ebola epidemic in West Africa could infect 20,000 people, warning that an international effort costing almost half a billion dollars is needed.» Read More
More than 2 million people who got health insurance under Obama's law have data discrepancies that could jeopardize coverage for some.
But Merck chief Kenneth Frazier also said the government needs to modify its high corporate tax code to level the playing field for American companies.
One of the nation's top privately-run Medicare insurance plans faces a federal investigation into allegations that it overbilled the government.
Former Bush administration official Josh Valdez alleges his ex-employer cheated the government out of millions annually, charges the company denies.
A Los Angeles doctor has been charged with helping bilk Medicare out of more than $33 million.
Clovis shares fell to a 52-week low Tuesday on concerns its cancer drug won't be able to compete with rival AstraZeneca.
There is market rumor and speculation that Dublin-based, U.K.-listed pharma company Shire is a takeover target.
Chicago filed a lawsuit against five pharmaceutical companies, accusing them of concealing the risks associated with certain painkillers.
CNBC pharma reporter Meg Tirrell speaks with RBC Capital Markets analyst Michael Yee at the annual ASCO conference about the big moves in drug company stocks on Monday.
In 2012, hospitals charged more for every one of 98 common ailments that could be compared to the previous year.
CNBC biotech & pharma reporter Meg Tirrell talks to Richard Pazdur, the FDA's cancer czar about how far we've come in cancer treatment, breakthrough designations and if chemotherapy will soon be a thing of the past.
Thousands of oncologists, investors, researchers and analysts descended on Chicago for the annual ASCO, the year's biggest cancer research meeting.
CNBC's Meg Tirrell and Daniel O'Day, Roche Holdings COO, discuss the latest developments in immunotherapy and treating bladder cancer.
CNBC's Meg Tirrell and Roger Perlmutter, Merck Research Laboratories president, discuss the latest data on advanced melanoma and which new drugs are in Merck's pipeline.
CNBC's Meg Tirrell and Briggs Morrison, AstraZeneca CMO, discuss Pfizer's failed bid for AstraZeneca and the latest treatment for lung cancer.
Valeant and ally Pershing Square prepared to take its $53.8 billion takeover bid for Allergan directly to shareholders.
In the midst of e-cigarette regulation decisions, the FDA has included lost consumer enjoyment from less smoking in cost-benefit analysis.
Patients can try new once-a-day tablets that dissolve quickly under the tongue and raise tolerance to grass or ragweed pollen, much like the shots.
A new study suggests that applying a tax based on the amount of calories contained in sugary drinks would be effective, the NYT reports.
Religious leaders say the money that would flow to states and businesses if they expanded Medicaid eligibility is just too good to pass up.
Get the best of CNBC in your inbox